Hemophilia recognized as a disorder characterized by excessive bleeding, has...
Dr Fred Locke from Moffitt Cancer Center in Florida shares the data that were...
The current standard of care for patients with NDMM involves four cycles of VRd...
The ZUMA-12 study represents a phase 2 clinical trial aimed at investigating...
Allogeneic CAR T-cell therapies represent a potentially readily accessible...
The therapeutic potential of inhibiting NETs in various pathological conditions...
Dr Sharman presents the 6-year follow-up outcomes of the ELEVATE-TN study, a...
Dr Jason Westin, hematologist at Texas MD Anderson Cancer Center, Houston gives...
Prof. Stephan Stilgenbauer, hematologist at the Ulm University in Germany...
Prof. Ann Janssens, hematologist at UZ Leuven, discusses the outcomes of the...